Cover Image

HARDBACK
$52.95



View/Hide Left Panel

of cases are slightly higher in men than in women, the number of QALYs lost due to disease in women is over 200 fold that in men. The more severe nature of the sequelae of infection in women and the chronic nature of several of the sequelae account for this large difference.

If a vaccine program for N. gonorrhea were implemented today and the vaccine was 100% efficacious and utilized by 100% of the target population, the annualized present value of the health care costs saved would be $440 million. Using committee assumptions of less-than-ideal efficacy and utilization and including time and monetary costs until a vaccine program is implemented, the annualized present value of the health care costs saved would be $92.1 million.

If a vaccine program for N. gonorrhea were implemented today and the vaccine was 100% efficacious and utilized by 100% of the target population, the annualized present value of the program cost would be $680 million. Using committee assumptions of less-than-ideal efficacy and utilization and including time and monetary costs until a vaccine program is implemented, the annualized present value of the program cost would be $190 million.

Using committee assumptions of time and costs until licensure, the fixed cost of vaccine development has been amortized and is $10.8 million for a N. gonorrhea vaccine.

If a vaccine program were implemented today and the vaccine was 100% efficacious and utilized by 100% of the target population, the annualized present value of the cost per QALY gained is $1,000. Using committee assumptions of less-than-ideal utilization and including time and monetary costs until a vaccine program is implemented, the annualized present value of the cost per QALY gained is $2,300.

See Chapters 4 and 5 for details on the methods and assumptions used by the committee for the results reported.

READING LIST

Alexander LL, Treiman K, Clarke P. A National Survey of Nurse Practitioner Chlamydia Knowledge and Treatment Practices of Female Patients. Nurse Practitioner 1996; 21:48, 51–4.


Gutman, LT. Gonorrhea. In: Textbook of Pediatric Infectious Diseases. RD Feigin and JD Cherry eds. Philadelphia, PA: WB Saunder Company, 1992, pp. 540–552.


Handsfield HH, Sparling PF. Neisseria Gonorrhoeae. In: Principles and Practice of Infectious Diseases. GL Mandell, JE Bennett, Dolin R eds. New York, NY: Churchill Livingstone, 1995, pp. 1909–1926.


Magid D, Douglas JM, Schwartz JS. Doxycycline Compared with Azithromycin for Treating Women with Genital Chlamydia Trachomatis Infections: An Incremental Cost-Effectiveness Analysis. Annals of Internal Medicine 1996; 124:389–99.


U.S. Bureau of the Census. Statistical Abstract of the U.S.: 1995 (115th edition). Washington, D.C. 1995.



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement